Kailera Therapeutics Secures $600M Series B Funding Led by Bain Capital Private Equity

Why It Matters

The large raise signals strong market confidence in obesity treatments and equips Kailera to advance a potentially market‑changing weight‑loss drug through late‑stage trials, positioning it for a significant commercial opportunity.

Deal Summary

Kailera Therapeutics announced a $600 million Series B round to advance its obesity drug pipeline, with Bain Capital Private Equity as the lead investor. The round also attracted a slate of institutional investors including CPP Investments, Qatar Investment Authority, and Royalty Pharma, among others.